NEW YORK (GenomeWeb News) – BG Medicine today reported third quarter revenues of $1 million, up 56 percent from $641,000 in the third quarter of 2012.

The revenue increase was driven by $1 million in revenues from sales of the company's BGM Galectin-3 test, a 64 percent jump from the $610,000 it posted in Q3 2012. BG also reported $23,000 in revenues from its services business, down 26 percent from $31,000 a year ago.

The company's revenues matched the average Wall Street estimate of $1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.